# Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

> **NCT03664921** · PHASE2 · COMPLETED · sponsor: **Syntrix Biosystems, Inc.** · enrollment: 55 (actual)

## Conditions studied

- Diabetic Neuropathies
- Neuropathic Pain
- Pain, Chronic

## Interventions

- **DRUG:** Omnitram Oral Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03664921
- **Lead sponsor:** Syntrix Biosystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664921, "Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT03664921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*